DAYBREAK Supports Zenkuda Filing and Extends Kodiak Platform

Company Kodiak Sciences Event Type Phase 3 Results Modality Antibody-Biopolymer Conjugate Asset Zenkuda; Tabirafusp Alfa Tedromer Target VEGF; IL-6 Disease Area Wet Age-Related Macular Degeneration Summary Kodiak Sciences reported that both Zenkuda and tabirafusp alfa tedromer met the one-year visual-acuity noninferiority endpoint versus aflibercept in…